self-injectable extended-release remdesivir (SelfExRem) / St John's University - LARVOL DELTA

Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment. (PubMed, Int J Pharm) - "In vitro release of all the batches were carried out in 1% v/v tween 80 in phosphate buffer saline. The study indicated that SelfExRem developed with15% w/v PLGA(75:25) provided a steady release of drug for 48 h and may be a breakthrough approach for the treatment of COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

St. John’s Pharmacy Professors Develop Dosage Alternative for COVID-19 Medication (St. John's University) - "A team of professors from the College of Pharmacy and Health Sciences at St. John’s University have applied for a patent for a self-injectable, extended-release dosage of the antiviral medication Remdesivir....'We have developed a dosage form (SelfExRem) of RDV that a COVID-19 positive patient can self-administer, either manually, by autoinjector'....'SelfExRem showed continuous release of RDV over two to four days in our in vitro experiments'....US patent application (63/082,322) for SelfExRem is pending. Drs. Patel and Reznik plan to conduct a pharmacokinetic study in animals and seek a collaborator to test SelfExRem in the SARS-CoV-2 animal model before moving forward with clinical application."

Patent • Preclinical • Infectious Disease • Novel Coronavirus Disease